|
|
|
|
|
|
Free Newsletters
Archive
My eNewsletters
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Login
Become a Member
Discussion Forums
FAQ
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Career Definitions
Labor Market Reports
Education & Training
Regions
Market Summary
News
IPOs
Company Profiles
Companies
Events
BioPharm Insight
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
Precision BioSciences Announces that the European Patent Office Issues Written Decision Confirming CELLECTIS SA's Loss of Patent Protection for Single-Chain Meganucleases in Europe
3/11/2010
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc., today announced that the Opposition Division of the European Patent Office (EPO) has issued a written decision confirming its November 18, 2009 revocation of the previously granted claims of Cellectis’ European Patent No. 1 485 475. As previously reported, after an oral hearing in an Opposition Proceeding initiated by Precision BioSciences, Cellectis’ previously granted claims to single-chain meganucleases, including those derived from I-CreI, as well as Cellectis’ claims to most classes of hybrid meganucleases, were revoked in their entirety. As a result of the interlocutory decision, Cellectis’ patent has been severely restricted such that it now includes only claims limited to hybrid meganucleases formed by the fusion of an N-terminal of the I-DmoI meganuclease to a domain derived from the I-CreI meganuclease.
|
|
|
|
|
|
|
|
|
|
|
|